Kuros Biosciences Treats First Patient in Spinal Fusion Trial with Fibrin-PTH

Kuros Biosciences announced treatment of the first patient in the STRUCTURE trial investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) in patients with degenerative disc disease.

STRUCTURE is a prospective, randomized, controlled, single-blind, dose-finding, multi-center study with the primary endpoint of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us